Table 3.
The effect of genotype and stage of amyloidosis on spontaneous cholinergic activity
| Parameter tested | Genotype (df = 1) |
Pathologic stage (df = 2) |
Interaction (df = 2) |
|||
|---|---|---|---|---|---|---|
| F | p | F | p | F | p | |
| Figure 9, two-way ANOVA, effects of genotype and pathologic stage | ||||||
| Probability of spontaneous transients in rewarded trials | 1.121160445 | 3.00E-01 | 3.51E + 00 | 4.58E-02 | 6.322376366 | 6.23E-03 |
| Probability of spontaneous transients in shock trials | 16.57845946 | 4.40E-04 | 9.43E + 00 | 9.50E-04 | 3.424534352 | 4.92E-02 |
| Total cumulative energy in rewarded trials | 0.563153766 | 4.60E-01 | 4.04E + 00 | 3.08E-02 | 6.038374819 | 7.51E-03 |
| Total cumulative energy in shock trials | 11.64275947 | 2.29E-03 | 10.0043799 | 6.92E-04 | 5.132141141 | 1.39E-02 |
The probability of spontaneous transients, and the resulting cumulative cholinergic response across a session, significantly differ between WT and APP mice under appetitive and trace conditioning. This difference is accounted for by spontaneous hyperactivity at the mid stage in APP mice, which occurs at the onset of deficient cholinergic signaling.